Oral agent shows durable improvement in SUI patients

San Diego-Treatment with the dual neurotransmitter reuptake inhibitor duloxetine (Yentreve) results in durable improvement in symptoms of stress urinary incontinence, according to a study of open-label transition from placebo to active therapy.

Related Content:

Drug TherapyFemale Urology

Dr. Zillioux discusses same-day discharge for FPMRS procedures

Dr. Casey Seideman on ensuring women are considered for AUA awards

Dr. Casey Seideman on why women should consider specializing in urology